2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 5, 2017

9:00AM-11:00AM: Abstract Number: 551

Comparison of Drug Tolerability and Discontinuation Reasons between 7 Biologics in Patients with Rheumatoid Arthritis -Results from Kansai Consortium for Well-Being of Rheumatic Disease Patients (ANSWER cohort)-

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster I: Comorbidities and Adverse Events; Efficacy and Safety of Small Molecules

9:00AM-11:00AM: Abstract Number: 310

Comparison of Flexed and Extended Knee Arthrocentesis and the Role of Constant Compression

Orthopedics, Low Back Pain and Rehabilitation Poster

9:00AM-11:00AM: Abstract Number: 539

Comparison of Oral Versus Parenteral Methotrexate in Rheumatoid Arthritis: A Meta-Analysis

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster I: Comorbidities and Adverse Events; Efficacy and Safety of Small Molecules

9:00AM-11:00AM: Abstract Number: 334

Comparison of Outcomes in Osteoporosis in Patients on Denosumab between Standard and Non-Standard Dosing Intervals

ARHP Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 474

Comparison of Tofacitinib Efficacy in Patients with Moderate Vs Severe Rheumatoid Arthritis: Pooled Analysis of Phase 3 Studies

Rheumatoid Arthritis – Clinical Aspects Poster I: Treatment Patterns and Response

9:00AM-11:00AM: Abstract Number: 682

Complement Activation in Peripheral Blood in Relation to Lupus, Antiphospholipid and Rheumatoid Arthritis Autoantibodies: Insights from Clinical Laboratory Evaluations

Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster I: Biomarkers and Outcomes

9:00AM-11:00AM: Abstract Number: 568

Complement Consumption As a Predictor of Pulmonary Manifestation in Patients with Primary Sjögren’s Syndrome: Results from a Unicentric Observational Study

Sjögren's Syndrome Poster I: Translational Research

9:00AM-11:00AM: Abstract Number: 561

Comprehensive Immuno-Phenotyping of Follicular Helper T Cell and B Cell Subpopulations in Primary Sjögren’s Syndrome

Sjögren's Syndrome Poster I: Translational Research

9:00AM-11:00AM: Abstract Number: 309

Compression Assisted Arthrocentesis and Intraarticular Injection

Orthopedics, Low Back Pain and Rehabilitation Poster

9:00AM-11:00AM: Abstract Number: 201

Computer Learning (artificial intelligence) to Create a Computer-Based Triage Tool Classifying Referrals As Inflammatory or Non-Inflammatory Requiring Only Patient Reported Information

Health Services Research Poster I

9:00AM-11:00AM: Abstract Number: 546

Concomitant Hydroxychloroquine Impact on Anti-TNF Persistence in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster I: Comorbidities and Adverse Events; Efficacy and Safety of Small Molecules

9:00AM-11:00AM: Abstract Number: 110

Consensus-Building on a Rheumatology Musculoskeletal Ultrasound Scanning Protocol for Rheumatology Fellowship Programs

Education Poster

9:00AM-11:00AM: Abstract Number: 604

Consistent Safety Profile with up to 4 Years of Apremilast Treatment: Analysis of Data from 1,493 Subjects with Psoriatic Arthritis in 3 Large, Phase III, Long-Term Studies

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster I

9:00AM-11:00AM: Abstract Number: 375

Controlled Discontinuation of Colchicine Therapy in Familial Mediterranean Fever Patients with Single MEFV Mutation

Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster I: Autoinflammatory Disorders and Miscellaneous

9:00AM-11:00AM: Abstract Number: 62

Convergence of Joint Repair and Pain Pathways Via Nerve Growth Factor and p75 Expressing Mesenchymal Stem Cells in Established Osteoarthritis

Biology and Pathology of Bone and Joint Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].